Five New Genetic Variants Linked With Glioma Identified
the ONA take:
Five new genetic variants associated with glioma have been identified in the biggest ever study of DNA in patients within this population, according to a study published in Nature Communications.
Richard Houlston, MD, PhD, of The Institute of Cancer Research and an international team analyzed DNA from more than 5,637 patients with glioma from Europe, the United States, and Canada, and compared them with 9,158 patients without the disease.
Each variant they found was a one-letter difference in the DNA code that was associated with an increased risk of glioma in those who have it, thus bringing the total number of genetic variants linked to glioma to 12.
One variant in particular was linked with a 23% increased risk of glioblastoma, an aggressive form of glioma with an average survival of 10 to 15 months after diagnosis.
“We believe our study is the largest ever conducted of the genetics of glioma – the most common form of brain cancer – and it provides firm evidence that susceptibility to the disease is in part inherited,” Houlston said.
Five new genetic variants associated with glioma have been identified in the biggest ever study of DNA in patients within this population.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Robotic Surgery Provides Good Outcomes and Survival in Oropharyngeal Cancer
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Definitive IMRT Associated With Shorter Feeding Tube Placement Duration in HNC
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|